Can patients with recurrent Henoch-Schönlein purpura receive the COVID-19 vaccine?

Allergic purpura is a relatively common condition that can adversely affect both physical health and appearance, and it often recurs. During such a period, individuals may also be due for COVID-19 vaccination—but it remains unclear whether vaccination is safe. Can individuals with recurrent allergic purpura receive the COVID-19 vaccine?

Can individuals with recurrent allergic purpura receive the COVID-19 vaccine?

In general, individuals with allergic purpura may receive the COVID-19 vaccine—provided they are not experiencing an acute flare-up. If allergic purpura developed following prior COVID-19 vaccination but has since resolved without recurrence or systemic symptoms, re-vaccination may be considered. However, administering the vaccine during an active (acute) phase of allergic purpura may exacerbate the disease and potentially compromise vaccine efficacy. Therefore, vaccination should be deferred until the condition is fully stabilized. Following diagnosis of allergic purpura, prompt medical evaluation—including allergen testing—is strongly recommended. In daily life, antiallergic medications may also be used to help reduce the frequency of recurrences.

In cases of recurrent allergic purpura involving major organ systems—such as Henoch-Schönlein nephritis or gastrointestinal involvement—additional treatment with glucocorticoids and immunosuppressive agents may be required. Triggers for disease flares include intense physical activity, certain infections, or repeated exposure to allergens. Notably, some recurrences are linked to lifestyle factors.

For patients with allergic purpura, the top priority is identifying and avoiding the causative allergen(s). Second, dietary modifications are advised—particularly limiting intake of high-protein foods (especially exogenous proteins) and other potentially irritating or allergenic foods. We hope this information proves helpful!